On January 9, 2006, Protein Design Labs and its wholly-owned subsidiary ESP Pharma became known as PDL BioPharma. The transition to a new name coincides with the integration of the company's former subsidiary, ESP Pharma into Protein Design Labs, creating a single organization and operating structure, now known as PDL BioPharma. PDL BioPharma has chosen this new name to better reflect its status as a commercial biopharmaceutical company focused on discovering, developing and marketing innovative therapies for serious or life-threatening illnesses.
R&D
To view this information, you must subscribe to Partneringtools.
Partnerships
To view this information, you must subscribe to Partneringtools.
Deals
To view this information, you must subscribe to Partneringtools.
Senior management
To view this information, you must subscribe to Partneringtools.
Board of directors
To view this information, you must subscribe to Partneringtools.
Head office
To view this information, you must subscribe to Partneringtools.